Effect of lacidipine on blood pressure and endothelial function in mild-to-moderate essential hypertension patients with diabetes in Korea

Dae Hee Kim, Il Young Oh, Hae Young Lee, Yong Jin Kim, Hyo Soo Kim, Cheol Ho Kim, Byung Hee Oh, Kwon Sam Kim, Doo Il Kim, Young Dae Kim, Kyu Hyung Ryu, Si Hoon Park, Sang Hong Baek, Dong Gu Shin, Wan Joo Shim, Tae Hoon Ahn, Seok Kyu Oh, Seung Hwan Lee, Sung Yun Lee, Myung Ho JeongWook Sung Chung, Jun Young Jeong, So Yeon Choi, Si Wan Choi, Min Su Hyon

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background and Objectives: The aim of this study was to evaluate the efficacy of lacidipine in reducing blood pressure (BP) and to determine its effect on endothelial function in mild-to-moderate hypertensive patients with type 2 diabetes mellitus (DM). Subjects and Methods: This was a prospective, multicenter, open-label, single-arm study, enrolling 290 patients with mild-to-moderate hypertension and type 2 DM. Patients were initially treated with 2 mg lacidipine orally once daily for 4 weeks, which was then increased as necessary every 4 weeks to a maximal dose of 6 mg daily. The primary endpoint was the mean change in systolic blood pressure (SBP) from baseline after 12 weeks of treatment. Secondary endpoints included mean changes in diastolic blood pressure (DBP), flow-mediated vasodilatation (FMD), and serum concentrations of biochemical markers such as high-sensitivity C-reactive protein (hs-CRP), monocyte chemo-attractant protein-1 (MCP-1), matrix metalloproteinase-9 (MMP-9), and plasminogen activator inhibitor-1 (PAI-1). Results: Lacidipine treatment significantly reduced SBP by -13.4±13.0 mmHg (p<0.001) and DBP by -6.2±9.3 mmHg (p<0.001). Lacidipine treatment did not improve endothelial-dependent vasodilatation, despite significantly improved nitroglycerin-induced, endothelial-independent vasodilatation. MCP-1 levels significantly decreased from 283.66±110.08 pg/mL to 257.83±100.23 pg/mL (p<0.001); whereas there were no significant changes in the levels of hs-CRP, MMP-9, or PAI-1. Conclusion: Twelve weeks of treatment with lacidipine was effective and well tolerated in mild-to-moderate hypertensive patients with type 2 DM. In spite of inducing a significant reduction in MCP-1 levels, lacidipine did not improve endothelial function.

Original languageEnglish
Pages (from-to)632-638
Number of pages7
JournalKorean Circulation Journal
Volume40
Issue number12
DOIs
Publication statusPublished - 2010 Dec 1

Fingerprint

Korea
Blood Pressure
Vasodilation
Type 2 Diabetes Mellitus
Monocytes
Plasminogen Activator Inhibitor 1
Matrix Metalloproteinase 9
C-Reactive Protein
Essential Hypertension
lacidipine
Proteins
Nitroglycerin
Therapeutics
Biomarkers
Hypertension
Serum

Keywords

  • Diabetes mellitus
  • Endothelium
  • Hypertension
  • Lacidipine

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Effect of lacidipine on blood pressure and endothelial function in mild-to-moderate essential hypertension patients with diabetes in Korea. / Kim, Dae Hee; Oh, Il Young; Lee, Hae Young; Kim, Yong Jin; Kim, Hyo Soo; Kim, Cheol Ho; Oh, Byung Hee; Kim, Kwon Sam; Kim, Doo Il; Kim, Young Dae; Ryu, Kyu Hyung; Park, Si Hoon; Baek, Sang Hong; Shin, Dong Gu; Shim, Wan Joo; Ahn, Tae Hoon; Oh, Seok Kyu; Lee, Seung Hwan; Lee, Sung Yun; Jeong, Myung Ho; Chung, Wook Sung; Jeong, Jun Young; Choi, So Yeon; Choi, Si Wan; Hyon, Min Su.

In: Korean Circulation Journal, Vol. 40, No. 12, 01.12.2010, p. 632-638.

Research output: Contribution to journalArticle

Kim, DH, Oh, IY, Lee, HY, Kim, YJ, Kim, HS, Kim, CH, Oh, BH, Kim, KS, Kim, DI, Kim, YD, Ryu, KH, Park, SH, Baek, SH, Shin, DG, Shim, WJ, Ahn, TH, Oh, SK, Lee, SH, Lee, SY, Jeong, MH, Chung, WS, Jeong, JY, Choi, SY, Choi, SW & Hyon, MS 2010, 'Effect of lacidipine on blood pressure and endothelial function in mild-to-moderate essential hypertension patients with diabetes in Korea', Korean Circulation Journal, vol. 40, no. 12, pp. 632-638. https://doi.org/10.4070/kcj.2010.40.12.632
Kim, Dae Hee ; Oh, Il Young ; Lee, Hae Young ; Kim, Yong Jin ; Kim, Hyo Soo ; Kim, Cheol Ho ; Oh, Byung Hee ; Kim, Kwon Sam ; Kim, Doo Il ; Kim, Young Dae ; Ryu, Kyu Hyung ; Park, Si Hoon ; Baek, Sang Hong ; Shin, Dong Gu ; Shim, Wan Joo ; Ahn, Tae Hoon ; Oh, Seok Kyu ; Lee, Seung Hwan ; Lee, Sung Yun ; Jeong, Myung Ho ; Chung, Wook Sung ; Jeong, Jun Young ; Choi, So Yeon ; Choi, Si Wan ; Hyon, Min Su. / Effect of lacidipine on blood pressure and endothelial function in mild-to-moderate essential hypertension patients with diabetes in Korea. In: Korean Circulation Journal. 2010 ; Vol. 40, No. 12. pp. 632-638.
@article{578a4749bdff457fbcaaa7a4fc8851df,
title = "Effect of lacidipine on blood pressure and endothelial function in mild-to-moderate essential hypertension patients with diabetes in Korea",
abstract = "Background and Objectives: The aim of this study was to evaluate the efficacy of lacidipine in reducing blood pressure (BP) and to determine its effect on endothelial function in mild-to-moderate hypertensive patients with type 2 diabetes mellitus (DM). Subjects and Methods: This was a prospective, multicenter, open-label, single-arm study, enrolling 290 patients with mild-to-moderate hypertension and type 2 DM. Patients were initially treated with 2 mg lacidipine orally once daily for 4 weeks, which was then increased as necessary every 4 weeks to a maximal dose of 6 mg daily. The primary endpoint was the mean change in systolic blood pressure (SBP) from baseline after 12 weeks of treatment. Secondary endpoints included mean changes in diastolic blood pressure (DBP), flow-mediated vasodilatation (FMD), and serum concentrations of biochemical markers such as high-sensitivity C-reactive protein (hs-CRP), monocyte chemo-attractant protein-1 (MCP-1), matrix metalloproteinase-9 (MMP-9), and plasminogen activator inhibitor-1 (PAI-1). Results: Lacidipine treatment significantly reduced SBP by -13.4±13.0 mmHg (p<0.001) and DBP by -6.2±9.3 mmHg (p<0.001). Lacidipine treatment did not improve endothelial-dependent vasodilatation, despite significantly improved nitroglycerin-induced, endothelial-independent vasodilatation. MCP-1 levels significantly decreased from 283.66±110.08 pg/mL to 257.83±100.23 pg/mL (p<0.001); whereas there were no significant changes in the levels of hs-CRP, MMP-9, or PAI-1. Conclusion: Twelve weeks of treatment with lacidipine was effective and well tolerated in mild-to-moderate hypertensive patients with type 2 DM. In spite of inducing a significant reduction in MCP-1 levels, lacidipine did not improve endothelial function.",
keywords = "Diabetes mellitus, Endothelium, Hypertension, Lacidipine",
author = "Kim, {Dae Hee} and Oh, {Il Young} and Lee, {Hae Young} and Kim, {Yong Jin} and Kim, {Hyo Soo} and Kim, {Cheol Ho} and Oh, {Byung Hee} and Kim, {Kwon Sam} and Kim, {Doo Il} and Kim, {Young Dae} and Ryu, {Kyu Hyung} and Park, {Si Hoon} and Baek, {Sang Hong} and Shin, {Dong Gu} and Shim, {Wan Joo} and Ahn, {Tae Hoon} and Oh, {Seok Kyu} and Lee, {Seung Hwan} and Lee, {Sung Yun} and Jeong, {Myung Ho} and Chung, {Wook Sung} and Jeong, {Jun Young} and Choi, {So Yeon} and Choi, {Si Wan} and Hyon, {Min Su}",
year = "2010",
month = "12",
day = "1",
doi = "10.4070/kcj.2010.40.12.632",
language = "English",
volume = "40",
pages = "632--638",
journal = "Korean Circulation Journal",
issn = "1738-5520",
publisher = "Korean Society of Circulation",
number = "12",

}

TY - JOUR

T1 - Effect of lacidipine on blood pressure and endothelial function in mild-to-moderate essential hypertension patients with diabetes in Korea

AU - Kim, Dae Hee

AU - Oh, Il Young

AU - Lee, Hae Young

AU - Kim, Yong Jin

AU - Kim, Hyo Soo

AU - Kim, Cheol Ho

AU - Oh, Byung Hee

AU - Kim, Kwon Sam

AU - Kim, Doo Il

AU - Kim, Young Dae

AU - Ryu, Kyu Hyung

AU - Park, Si Hoon

AU - Baek, Sang Hong

AU - Shin, Dong Gu

AU - Shim, Wan Joo

AU - Ahn, Tae Hoon

AU - Oh, Seok Kyu

AU - Lee, Seung Hwan

AU - Lee, Sung Yun

AU - Jeong, Myung Ho

AU - Chung, Wook Sung

AU - Jeong, Jun Young

AU - Choi, So Yeon

AU - Choi, Si Wan

AU - Hyon, Min Su

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Background and Objectives: The aim of this study was to evaluate the efficacy of lacidipine in reducing blood pressure (BP) and to determine its effect on endothelial function in mild-to-moderate hypertensive patients with type 2 diabetes mellitus (DM). Subjects and Methods: This was a prospective, multicenter, open-label, single-arm study, enrolling 290 patients with mild-to-moderate hypertension and type 2 DM. Patients were initially treated with 2 mg lacidipine orally once daily for 4 weeks, which was then increased as necessary every 4 weeks to a maximal dose of 6 mg daily. The primary endpoint was the mean change in systolic blood pressure (SBP) from baseline after 12 weeks of treatment. Secondary endpoints included mean changes in diastolic blood pressure (DBP), flow-mediated vasodilatation (FMD), and serum concentrations of biochemical markers such as high-sensitivity C-reactive protein (hs-CRP), monocyte chemo-attractant protein-1 (MCP-1), matrix metalloproteinase-9 (MMP-9), and plasminogen activator inhibitor-1 (PAI-1). Results: Lacidipine treatment significantly reduced SBP by -13.4±13.0 mmHg (p<0.001) and DBP by -6.2±9.3 mmHg (p<0.001). Lacidipine treatment did not improve endothelial-dependent vasodilatation, despite significantly improved nitroglycerin-induced, endothelial-independent vasodilatation. MCP-1 levels significantly decreased from 283.66±110.08 pg/mL to 257.83±100.23 pg/mL (p<0.001); whereas there were no significant changes in the levels of hs-CRP, MMP-9, or PAI-1. Conclusion: Twelve weeks of treatment with lacidipine was effective and well tolerated in mild-to-moderate hypertensive patients with type 2 DM. In spite of inducing a significant reduction in MCP-1 levels, lacidipine did not improve endothelial function.

AB - Background and Objectives: The aim of this study was to evaluate the efficacy of lacidipine in reducing blood pressure (BP) and to determine its effect on endothelial function in mild-to-moderate hypertensive patients with type 2 diabetes mellitus (DM). Subjects and Methods: This was a prospective, multicenter, open-label, single-arm study, enrolling 290 patients with mild-to-moderate hypertension and type 2 DM. Patients were initially treated with 2 mg lacidipine orally once daily for 4 weeks, which was then increased as necessary every 4 weeks to a maximal dose of 6 mg daily. The primary endpoint was the mean change in systolic blood pressure (SBP) from baseline after 12 weeks of treatment. Secondary endpoints included mean changes in diastolic blood pressure (DBP), flow-mediated vasodilatation (FMD), and serum concentrations of biochemical markers such as high-sensitivity C-reactive protein (hs-CRP), monocyte chemo-attractant protein-1 (MCP-1), matrix metalloproteinase-9 (MMP-9), and plasminogen activator inhibitor-1 (PAI-1). Results: Lacidipine treatment significantly reduced SBP by -13.4±13.0 mmHg (p<0.001) and DBP by -6.2±9.3 mmHg (p<0.001). Lacidipine treatment did not improve endothelial-dependent vasodilatation, despite significantly improved nitroglycerin-induced, endothelial-independent vasodilatation. MCP-1 levels significantly decreased from 283.66±110.08 pg/mL to 257.83±100.23 pg/mL (p<0.001); whereas there were no significant changes in the levels of hs-CRP, MMP-9, or PAI-1. Conclusion: Twelve weeks of treatment with lacidipine was effective and well tolerated in mild-to-moderate hypertensive patients with type 2 DM. In spite of inducing a significant reduction in MCP-1 levels, lacidipine did not improve endothelial function.

KW - Diabetes mellitus

KW - Endothelium

KW - Hypertension

KW - Lacidipine

UR - http://www.scopus.com/inward/record.url?scp=79551696061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551696061&partnerID=8YFLogxK

U2 - 10.4070/kcj.2010.40.12.632

DO - 10.4070/kcj.2010.40.12.632

M3 - Article

C2 - 21267385

AN - SCOPUS:79551696061

VL - 40

SP - 632

EP - 638

JO - Korean Circulation Journal

JF - Korean Circulation Journal

SN - 1738-5520

IS - 12

ER -